Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vanda Pharmaceuticals (VNDA) Intangibles (2016 - 2025)

Vanda Pharmaceuticals' Intangibles history spans 16 years, with the latest figure at $117.1 million for Q4 2025.

  • On a quarterly basis, Intangibles rose 2.62% to $117.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $117.1 million, a 2.62% increase, with the full-year FY2025 number at $117.1 million, up 2.62% from a year prior.
  • Intangibles hit $117.1 million in Q4 2025 for Vanda Pharmaceuticals, up from $108.8 million in the prior quarter.
  • Over the last five years, Intangibles for VNDA hit a ceiling of $121.4 million in Q4 2023 and a floor of $17.4 million in Q3 2023.
  • Historically, Intangibles has averaged $62.5 million across 5 years, with a median of $21.0 million in 2021.
  • Biggest five-year swings in Intangibles: fell 8.0% in 2023 and later skyrocketed 564.72% in 2024.
  • Tracing VNDA's Intangibles over 5 years: stood at $20.1 million in 2021, then decreased by 7.55% to $18.6 million in 2022, then skyrocketed by 553.75% to $121.4 million in 2023, then fell by 5.99% to $114.1 million in 2024, then grew by 2.62% to $117.1 million in 2025.
  • Business Quant data shows Intangibles for VNDA at $117.1 million in Q4 2025, $108.8 million in Q3 2025, and $110.6 million in Q2 2025.